NEW YORK (GenomeWeb News) – Molecular diagnostics developer Asuragen said today that Biomedical Diagnostics (BMD) will distribute its cancer assays in France.
The agreement covers Asuragen's Signature Oncology Portfolio, a line of multiplex assays used to detect mutations in solid and hematologic malignancies. The tests use RT-PCR and multiplex detection using the Luminex 100 or 200 systems.
The portfolio includes a research assay for KRAS and BRAF mutations, an IVD assay that uses RNA from blood or bone marrow to help diagnose certain leukemias, and an assay for simultaneous detection of common NPM1 mutations.
In addition, BMD will support Asuragen's efforts to establish clinical validation sites for the Signature KRAS/BRAF assay in France, Asuragen said.